

# Strategies for Successfully Diagnosing and Treating Tardive Dyskinesia: Enlisting the Help of Caregivers, Improving the Lives of Patients

## References

1. Caroff SN. Overcoming barriers to effective management of tardive dyskinesia. *Neuropsychiatr Dis Treat*. 2019;15:785-794.
2. Caroff SN, Aggarwal S, Yonan C. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. *J Comp Eff Res*. 2018;7(2):135-148.
3. National Institutes of Health. Tardive dyskinesia information page. 2021. Accessed February 1, 2021. <https://www.ninds.nih.gov/Disorders/All-Disorders/Tardive-Dyskinesia-Information-Page>
4. McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. *Qual Life Res*. 2019;28(12):3303-3312.
5. McEvoy JP, Kremens DE. Early recognition and treatment of tardive dyskinesia in patients with mood disorders and schizophrenia. *J Clin Psychiatry*. 2020;81(1).
6. Bhidayasiri R, Jitkriksadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. *J Neurol Sci*. 2018;389:67-75.
7. Barnett ML, Ray KN, Souza J, Mehrotra A. Trends in telemedicine use in a large commercially insured population, 2005-2017. *JAMA*. 2018;320(20):2147-2149.
8. Spivak S, Spivak A, Cullen B, et al. Telepsychiatry use in U.S. mental health facilities, 2010-2017. *Psychiatr Serv*. 2020;71(2):121-127.
9. Shore JH, Schneck CD, Mishkind MC. Telepsychiatry and the coronavirus disease 2019 pandemic—current and future outcomes of the rapid virtualization of psychiatric care. *JAMA Psychiatry*. 2020;77(12):p1211-1212.
10. Caroff SN, Yeomans K, Lenderking WR, et al. RE-KINECT: A prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. *J Clin Psychopharmacol*. 2020;40(3):259-268.
11. Ayyagari R, Goldschmidt D, Mu F, Caroff S, Carroll B. An experimental study to assess the professional and social consequences of mild-to-moderate tardive dyskinesia. *CNS Spectr*. 2020;25(2):275.
12. Depression and Bipolar Support Alliance. Survey: experiences with tardive dyskinesia. 2017. Accessed March 31, 2021. [https://www.dbsalliance.org/wp-content/uploads/2019/02/DBSA\\_Survey\\_Center\\_-\\_TD\\_2nd\\_survey.pdf](https://www.dbsalliance.org/wp-content/uploads/2019/02/DBSA_Survey_Center_-_TD_2nd_survey.pdf)
13. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. *Neurotherapeutics*. 2014;11(1):166-176.
14. Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. *Neuropsychiatr Dis Treat*. 2013;9:1371-1380.
15. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry*. 2004;161(2 Suppl):1-56.
16. Nierenberg AA. How to evaluate patients for tardive dyskinesia. *J Clin Psychiatry*. 2020;82(1):NU19047BR19041C.
17. Citrome L. Clinical management of tardive dyskinesia: five steps to success. *J Neurol Sci*. 2017;383:199-204.

## Strategies for Successfully Diagnosing and Treating Tardive Dyskinesia: Enlisting the Help of Caregivers, Improving the Lives of Patients

18. Caroff S, Cutler A, Tanner C, et al. Tardive dyskinesia symptom screening in real-world outpatient settings: Correlations between patient-, caregiver-, and clinician-reported assessments in the RE-KINECT study. *Psych Congress*. 2019. Accessed March 31, 2021. <https://www.psychcongress.com/posters/tardive-dyskinesia-symptom-screening-real-world-outpatient-settings-correlations-between>
19. Hauser RA, Meyer JM, Factor SA, et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. *CNS Spectr*. 2020;1-10.
20. Abnormal Involuntary Movement Scale (AIMS). Accessed March 31, 2021. <https://www.seattlechildrens.org/globalassets/documents/healthcare-professionals/pal/ratings/aims-rating-scale.pdf>
21. Schooler N, Kane J. Research diagnoses for tardive dyskinesia *Arch Gen Psychiatry*. 1982;39:486-487.
22. McEvoy JP. How to assess tardive dyskinesia symptom improvement with measurement-based care. *J Clin Psychiatry*. 2020;81(6):NU19047BR4C.
23. Saklad SR. Identifying tardive dyskinesia: risk factors, functional impact, and diagnostic tools. *J Clin Psychiatry*. 2020;81(1):TV18059BR1C.
24. Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. *BMC Psychiatry*. 2018;18(1):306.
25. Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B. Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia. *BMC Psychiatry*. 2020;20(1):365.
26. McEvoy JP. Selecting treatment for patients with tardive dyskinesia using safety and efficacy evidence. *J Clin Psychiatry*. 2020;81(6):NU19047BR3C.
27. Artukoglu BB, Li F, Szejko N, Bloch MH. Pharmacologic treatment of tardive dyskinesia: a meta-analysis and systematic review. *J Clin Psychiatry*. 2020;81(4):19r12798.
28. Hauser RA, Truong D. Tardive dyskinesia: out of the shadows. *J Neurol Sci*. 2018;389:1-3.
29. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. *Neurology*. 2017;88(21):2003-2010.
30. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. *Am J Psychiatry*. 2017;174(5):476-484.
31. McIntyre RS, Calabrese JR, Nierenberg AA, et al. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. *J Affect Disord*. 2019;246:217-223.
32. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Psychiatry*. 2017;4(8):595-604.
33. Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. *J Neurol Neurosurg Psychiatry*. 2019;90(12):1317-1323.

## Strategies for Successfully Diagnosing and Treating Tardive Dyskinesia: Enlisting the Help of Caregivers, Improving the Lives of Patients

34. Marder SR, Singer C, Lindenmayer J-P, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. *J Clin Psychopharmacol*. 2019;39(6):620-627.
35. Lindenmayer JP, Verghese C, Marder SR, et al. A long-term, open-label study of valbenazine for tardive dyskinesia. *CNS Spectr*. 2020:1-9.
36. Anderson KE, Stamler D, Davis MD, et al. Long-term deutetrabenazine treatment response in tardive dyskinesia by concomitant dopamine-receptor antagonists and baseline comorbidities [Psych Congress abstract 34]. *CNS Spectr*. 2019;24(1):193.
37. Sajatovic M, Alexopoulos GS, Burke J, Farahmand K, Siegert S. The effects of valbenazine on tardive dyskinesia in older and younger patients. *Int J Geriatr Psychiatry*. 2020;35(1):69-79.